ECTRIMS 2024: Tolebrutinib may target smoldering inflammation
WEB11 hours ago · by Lindsey Shapiro, PhD September 23, 2024. Sanofi’s tolebrutinib significantly delayed disability progression, by 31%, and increased the rates of disability improvement compared with a placebo ...
AB Science provides an update on the development of masitinib in ...
WEB8 hours ago · PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE DEVELOPMENT OF MASITINIB IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS POST ECTRIMS 2024 Paris, 23 September 2024, 5.45pm CET AB Science SA ...
ECTRIMS Conference 2024 | Copenhagen 18-20 September | ECTRIMS
WEBThe World's Largest MS Research Congress. ECTRIMS 2024 is the premier meeting place for researchers, clinicians and healthcare providers to collaborate on the next life-changing research and treatment options for people with MS and related diseases.
ECTRIMS 2024: Mavenclad sustains benefits in relapsing MS
WEB5 days ago · ECTRIMS 2024: MS relapse rates fall with 5 years on Briumvi September 6, 2024 News by Lindsey Shapiro, PhD 1-year fenebrutinib curbs nearly all disease activity in relapsing MS trial
ECTRIMS 2024: MS relapse rates fall with 5 years on Briumvi
WEB4 days ago · Annualized rate equals 1 relapse every 50 years, data show. by Lindsey Shapiro, PhD September 19, 2024. Continuous treatment with Briumvi (ublituximab) over five years was associated with low ...
The Effect of High- Vs Low- to Medium-Efficacy Treatments on …
WEB6 days ago · Study results presented at the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) demonstrated that high-efficacy disease-modifying treatments (HE-DMTs) significantly reduced progression independent of relapse activity (PIRA) rates compared with low- to moderate-efficacy disease-modifying treatments (LM-DMTs) in individuals with relapsing ...
ECTRIMS - European Committee for Treatment and Research in …
WEBSep 5, 2024 · ECTRIMS hosts the world’s largest and most influential congress devoted to basic and clinical research and care in multiple sclerosis. Our annual congresses bring together 9,000+ specialists from across the globe, offering a host of educational sessions, plenary lectures, posters and young investigator sessions, as well as meet-the-expert ...
Immunic Presents Key Vidofludimus Calcium Data at the 40th
WEB5 days ago · "Having four poster presentations on our lead asset, vidofludimus calcium, at the prestigious ECTRIMS Congress, illustrates the strength of the data generated for our drug candidate, to date, and ...
MSMilan 2023 - HOME | ECTRIMS
WEBThe 9th Joint ECTRIMS-ACTRIMS Meeting. 11-13 October 2023 | Milan, Italy. Key happenings at MSMilan2023. Welcome to the world’s largest research meeting in multiple sclerosis.
ECTRIMS 2024 - Medscape
WEBOct 23, 2023 · ECTRIMS 2021. Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2024 : Read clinically focused news coverage of key developments from ECTRIMS 2024.
Skip to content